MADRID and CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that the European Medicines Agency (EMA) has authorized its Clinical Trial Application (CTA) to initiate a Phase II study of iadademstat, Oryzon’s potent and selective LSD1 inhibitor currently in clinical development in oncology and hematology, for the treatment of essential thrombocythemia ...

展望2026年，公司预计营收将在27亿至29亿美元之间，押注于个性化医疗保健产品的销售增长，分析师 预期为27.4亿美元。单看第一季度，公司预计营收将在6亿至6.25亿美元之间，低于分析师预期的6.53亿 美元。 格隆汇2月24日｜在线远程医疗公司Hims&Hers Health公布，2025年第四季度营收同比增长28%至6.18亿 美元，略低于分析师预期的6.19亿美元；调整后每股净收益为0.08美元，去年同期为0.11美元。2025全 年营收同比增长59%至23.48亿美元，净利润为1.28亿美元，调整后EBITDA为3.18亿美元；订阅用户数 扩大至超过250万，同比增长13%。 ...

Hims & Hers Health (NYSE:HIMS) Q4 2025 Earnings call February 23, 2026 05:00 PM ET Company ParticipantsAndrew Dudum - Co-founder and CEOBill Newby - Head of Investor RelationsEric Percher - Partner of Pharma Supply Chain and Digital HealthGlen Santangelo - Managing DirectorMaria Ripps - Managing Director of Equity ResearchMark Mahaney - Senior Managing Director and Head of Internet ResearchYemi Okupe - CFOConference Call ParticipantsBrian Tanquilut - Senior Analyst of Healthcare Services and Digital Health ...

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $618 million, representing a year-over-year growth rate of 28% [25] - For the full fiscal year 2025, revenue reached $2.35 billion, reflecting a year-over-year growth rate of 59% [25] - Adjusted EBITDA for 2025 increased nearly 80% year-over-year to $318 million, with an Adjusted EBITDA margin of 14% [31] - Net income for the full year increased to $128 million, compared to the previous year [34] Business Line Data and Key Metrics Changes - The Hims brand in the US saw over 30% year-over-year revenue growth in 2025, despite a pivot away from generic sexual solutions [26] - The Hers brand continued to display triple-digit revenue growth, accounting for nearly 40% of U.S. revenue [27] - Approximately 65% of subscribers were utilizing a personalized treatment by the end of 2025, with monthly revenue per average subscriber increasing 11% year-over-year to $83 [24][25] Market Data and Key Metrics Changes - International revenue grew almost 400% year-over-year to $134 million, with expectations for this segment to become a more meaningful portion of overall revenue [30] - The company expects at least $200 million in revenue contributions from international markets in 2026, including from the acquisition of Eucalyptus [48] Company Strategy and Development Direction - The company aims to achieve $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030, focusing on consumer-centric healthcare [22] - Investments in technology and infrastructure are prioritized to enhance personalized care and expand operational capabilities [19][38] - The company plans to deepen its international presence and aims for a unified brand across major markets within the next 1-2 years [54] Management's Comments on Operating Environment and Future Outlook - Management believes the healthcare system must evolve towards a consumer-oriented model, similar to platforms like Netflix and Spotify [6] - The company is confident in its ability to navigate regulatory scrutiny and maintain growth through diverse offerings beyond GLP-1 treatments [56] - Management anticipates strong demand for weight loss solutions and expects subscriber growth to remain robust throughout 2026 [45] Other Important Information - The company has invested over $300 million in facilities over the last three years, expanding its operational footprint to over 1 million square feet [19] - The acquisition of Eucalyptus is expected to enhance the company's international capabilities and contribute significantly to revenue growth [43] Q&A Session Summary Question: What are the long-term priorities for global growth with the acquisition of Eucalyptus? - The company aims to target 10 key markets globally and achieve over $1 billion in incremental international revenue within a few years [54] Question: How will the company manage risks from potential regulatory scrutiny on GLP-1s? - Management emphasizes that the majority of revenue comes from offerings outside of weight loss and plans to continue expanding its diverse offerings [56]

Core Insights - Google DeepMind's CEO Demis Hassabis envisions a transformative future for AI, predicting that AI-designed drugs will enter clinical trials by 2026 and heralding a "golden age of discovery" in the next 10 to 15 years [2][4][58] Group 1: AI in Pharmaceuticals - Hassabis aims to leverage AI through his startup Isomorphic Labs to revolutionize drug development, targeting the initiation of clinical trials for the first AI-designed drug by early 2026 [4][30] - The company is currently working on 17 drug projects across various fields, including cancer and cardiovascular diseases, with plans to expand to hundreds of projects [4][28] - Traditional drug development is costly and time-consuming, averaging 10 years and billions of dollars with a success rate of only 10%, while AI could enhance efficiency by "hundreds of thousands of times" [4][28] Group 2: AI Model Developments - Hassabis confirmed that Google’s Gemini 3 has reached a "watershed moment," indicating significant advancements in its capabilities [5] - Google is restructuring its infrastructure to rapidly integrate the latest AI models into its products, aiming to revive the innovative spirit of its earlier years [5][44] Group 3: Future Applications of AI - Hassabis predicts that AI agents and more autonomous systems will start to emerge by the end of this year, allowing users to delegate entire tasks to them [6][52] - He highlighted the potential of smart glasses as a "killer app" for AI technology, envisioning a universal assistant that operates across various devices [6][55] - Optimism surrounds breakthroughs in robotics within the next 18 months, suggesting significant advancements in this field [7][53] Group 4: Vision for Humanity - Hassabis foresees a new "golden age" where human health will be transformed, with personalized medicine becoming a reality and AI addressing major challenges like the energy crisis [7][58] - He believes that advancements in AI could lead to a world rich in resources, enabling humanity to explore the galaxy [7][58] Group 5: Company Management and Strategy - Google DeepMind is merging its AI teams to enhance collaboration and efficiency, focusing on leveraging top talent for projects like Gemini [35][36] - The company is fostering a culture of rapid delivery and innovation, reminiscent of its earlier "golden age," to maintain a competitive edge in the AI landscape [38][44]

随后，团队利用该模型，模拟了一种极为罕见的遗传性胃病：磷酸甘露糖酶2相关性高胰岛素血症伴多 囊肾病和炎症性肠病（PMM2-HIPKD-IBD）。部分患儿除血糖与肾脏异常外，还伴有胃窦小凹增生 ——即胃黏膜出现异常增生组织，可能引发出血、炎症，甚至增加癌变风险。这些病变源于胃细胞功能 紊乱，过去难以深入研究。 如今，借助患者自身干细胞培育出的"迷你胃"，团队不仅能验证致病假设，还可高效筛选潜在药物，大 幅缩短新疗法从实验室走向临床的时间。 研究团队从患者胃组织中提取干细胞，在特殊培养条件下引导其发育成模拟真实胃功能的类器官。他们 分别培育出对应胃底、胃体和胃窦的三种独立类器官，再将其巧妙"组装"为一体，形成多功能整合结 构。这在国际上尚属首次。 来源：科技日报 这个"迷你胃"各部分不仅保留了原区域的生物学特征，还能像真正的胃一样相互协作，甚至能分泌胃酸 ——这是实现食物消化的关键一步。 科技日报记者 刘霞 团队认为，该"迷你胃"高度还原了胃窦至胃底的结构与功能，尤其在揭示罕见胃病机制方面展现出独特 优势。 来自英国伦敦大学学院和大奥蒙德街儿童医院的科学家携手，培育出全球首个包含完整关键结构的"迷 你胃"。这个仅 ...

Summary of Alignment Healthcare FY Conference Call Company Overview - **Company**: Alignment Healthcare (NasdaqGS:ALHC) - **Industry**: Healthcare Services, specifically Medicare Advantage plans Key Points and Arguments 1. **Vision and Mission**: Alignment Healthcare aims to create a seamless healthcare experience for seniors by aligning health plans, providers, and CMS with a focus on data fluidity and operational efficiency [3][4] 2. **Membership Growth**: The company has grown to over 275,000 members, with guidance suggesting it will reach close to 300,000 by year-end. Premium revenue is projected to approach $4 billion, with a growth rate of approximately 30% per year [4][10] 3. **Differentiation in Care Management**: Unlike competitors, Alignment Healthcare emphasizes care management and clinical delivery over traditional underwriting practices. The company believes that effective care delivery is essential for managing costs and improving patient outcomes [4][10] 4. **Cost Management**: The company identifies that 10%-20% of its population accounts for 70%-80% of medical loss ratio (MLR). By focusing on these high-need cohorts, Alignment Healthcare aims to provide proactive care, thereby reducing overall costs [5][8] 5. **Care Delivery Model**: The "Care Anywhere" model employs a multidisciplinary team to provide in-home care, which costs about 3% of premium revenue. This model is designed to ensure quality control and improve patient outcomes [8][9] 6. **Regulatory Compliance and Star Ratings**: 100% of members are in plans rated four stars or above, with three five-star plans. The company emphasizes the importance of high Star Ratings for financial incentives from CMS [14][15] 7. **Growth Strategy**: The company plans to continue expanding in California while also growing in other markets. It aims to invest in new markets starting in 2027, using cash flow from operations [17][30] 8. **Financial Performance**: The company reported a 58% growth in 2024 and a 31% growth in Q1 of the current year, with a focus on maintaining margins while expanding membership [11][15] 9. **Market Dynamics**: The company is positioned to benefit from upcoming changes in the risk adjustment model (V29) and anticipates a more favorable environment for growth starting in 2027 [26][36] 10. **Long-term Vision**: Alignment Healthcare aims to scale from 300,000 to 3 million members, focusing on maintaining quality and operational efficiency as it grows [20][21] Additional Important Insights - **Retention Rates**: The company has seen improved retention rates, indicating member satisfaction with service delivery [16][25] - **Market Share Opportunities**: There is significant potential for market share growth, particularly outside California, where the company has reported better gross profit metrics [18][24] - **Investment in Technology**: Continuous investment in data architecture and technology is crucial for scaling operations and maintaining competitive advantages [31][34] - **Cultural Commitment**: The company emphasizes a culture of quality and service, which is integral to its operational strategy and member satisfaction [14][21] This summary encapsulates the key insights from the Alignment Healthcare FY Conference Call, highlighting the company's growth trajectory, strategic focus, and commitment to improving healthcare for seniors.

Core Insights - The development of a gene-consistent human "lung chip" model by the Francis Crick Institute and AlveoliX represents a significant advancement in personalized treatment for respiratory diseases like tuberculosis [1][2][3] Group 1: Technology and Innovation - The lung chip utilizes induced pluripotent stem cells from a single donor to simulate individual alveolar breathing actions and infection responses, providing a new tool for personalized therapy [1] - The chip's design includes a specialized device that applies rhythmic three-dimensional stretching forces to mimic breathing, promoting the formation of microvilli on alveolar epithelial cells [1] Group 2: Disease Simulation and Research Implications - The team successfully simulated the early stages of tuberculosis infection by introducing macrophages derived from the same donor's stem cells and exposing the chip to Mycobacterium tuberculosis, resulting in observable pathological features [2] - The lung chip effectively replicates the early pulmonary responses to infection, offering a comprehensive view of disease progression that is typically difficult to observe in early stages [2] Group 3: Future Applications and Impact - This highly personalized microphysiological model could revolutionize drug development by allowing direct testing of drug efficacy and toxicity on the chip, reducing reliance on animal models and potentially accelerating candidate drug screening [3]

Group 1: Company Overview - Long Fung Group Holdings Limited has submitted its main board listing application to the Hong Kong Stock Exchange, with DBS Asia Capital as the sole sponsor [1] - The company holds a 5.2% market share, making it the largest pharmaceutical retailer in Hong Kong, and also the largest cosmetic retailer by average SKU per store [2][3] Group 2: Business Operations - Long Fung operates 29 retail stores in Hong Kong and various online channels, including its official website and major e-commerce platforms [2] - The company has a diverse product matrix covering 11 categories, including traditional Chinese medicine, Western medicine, health supplements, and cosmetics, with over 46,000 SKUs sold during the reporting period [2] Group 3: Financial Performance - Revenue has shown significant growth from HKD 1.094 billion in FY2023 to HKD 2.460 billion in FY2025, with a gross margin improvement from 24.9% to 31.6% during the same period [3][4] - The company transitioned from a loss of HKD 25.2 million in FY2023 to a profit of HKD 218 million in FY2025, with a tax-pre profit of HKD 59.9 million in Q1 FY2026, reflecting over 100% year-on-year growth [4][5] Group 4: Market Trends - The Hong Kong pharmaceutical market is projected to grow from approximately HKD 57.88 billion in 2020 to HKD 85.08 billion in 2024, with a compound annual growth rate (CAGR) of 10.1% [7] - Key structural trends driving market growth include the integration of traditional Chinese and Western medicine, and the rising demand for personalized healthcare solutions [8] Group 5: Competitive Landscape - The market is highly fragmented, with the top five retailers holding only 14.6% of the market share, indicating ongoing competitive challenges for Long Fung [8] - Rising operational costs, particularly in labor and warehouse rental, are expected to continue impacting profitability [9] Group 6: Strategic Outlook - The company aims to leverage capital market opportunities to strengthen its market position and operational efficiency while exploring new growth avenues [11] - Long Fung's financial performance reflects a complex interplay of growth potential and financial risks, necessitating close monitoring of its liquidity and equity structure [11]

Core Viewpoint - Long Fung Group has submitted its application for a mainboard listing on the Hong Kong Stock Exchange, positioning itself as the largest pharmaceutical retailer in Hong Kong with a market share of 5.2% and the largest beauty retail operator by average SKU per store, reflecting its deep understanding of consumer needs and strategic positioning over the past 30 years [1][2]. Company Overview - Long Fung Group operates a chain of retail drugstores under the "Long Fung" brand, with 29 physical stores and multiple online channels, achieving a market-leading position in Hong Kong's pharmaceutical retail sector [2]. - The company has a diverse product matrix covering 11 categories, including traditional Chinese medicine, Western medicine, health supplements, and beauty products, with over 46,000 SKUs sold during the reporting period [2]. Financial Performance - Revenue has shown significant growth from HKD 1.094 billion in the 2023 fiscal year to HKD 2.460 billion in the 2025 fiscal year, with a notable improvement in gross margin from 24.9% to 31.6% during the same period [3][4]. - The company transitioned from a loss of HKD 25.2 million in the 2023 fiscal year to a profit of HKD 218 million in the 2025 fiscal year, with a tax-pre profit of HKD 59.9 million in the first quarter of the 2026 fiscal year, indicating a remarkable turnaround [4]. Market Dynamics - The Hong Kong pharmaceutical market is projected to grow from approximately HKD 57.88 billion in 2020 to HKD 85.08 billion by 2024, with a compound annual growth rate (CAGR) of 10.1% [7]. - Key structural trends driving market growth include the integration of traditional Chinese and Western medicine and the rising demand for personalized healthcare solutions among consumers [8]. Competitive Landscape - The market is highly fragmented, with the top five retailers holding only 14.6% of the market share, indicating ongoing competitive challenges for Long Fung Group despite its leading position [8]. - Rising operational costs, particularly in labor and warehouse rental, are expected to continue impacting profitability, with average monthly salaries in the retail sector increasing from HKD 19,353.5 in 2020 to HKD 21,471.0 in 2024 [9]. Strategic Outlook - As Long Fung Group approaches its IPO, the focus will be on leveraging capital market opportunities to strengthen its market position and operational efficiency while exploring new growth avenues for sustainable expansion [11]. - The company faces a complex landscape of growth potential intertwined with financial risks, necessitating careful management of its liquidity structure and equity base to ensure long-term stability [11].